Vasculitis & polymyalgia rheumatica
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica
Authors' conclusion
Among patients with relapsed polymyalgia rheumatica, treatment with secukinumab plus a 24-week glucocorticoid taper resulted in a higher percentage of patients with remission and in lower cumulative glucocorticoid doses than a glucocorticoid taper alone.
Study context
- Population
- Patients with recently relapsed PMR
- Participants
- 381 patients
- Comparison
- Secukinumab 300 mg or 150 mg vs placebo for 52 weeks, all with a 24-week prednisone taper
- SEC-300n = 127
- SEC-150n = 127
- Placebon = 127reference
- Primary endpoint
- Sustained remission (no PMR signs or symptoms and no new GCA diagnosis warranting escape or rescue treatment) from week 12 until week 52
- Follow-up
- Week 52
Methodological detailsplacebo-controlled, 1:1:1 randomisation
- Placebo-controlled
- 1:1:1 randomisation
Primary result
As reported in the abstract
Sustained remission
SEC-300 vs Placebo: P < 0.001 for the comparison of each secukinumab dose with placebo · SEC-150 vs Placebo: P < 0.001 for the comparison of each secukinumab dose with placebo
Secondary outcomes
Annual cumulative GC dose (adjusted)
Safety
Serious adverse events
Serious adverse events
- Nasopharyngitis, hypersensitivity reactions, UTIs, fungal infections and back pain more common with secukinumab than placebo
Original publication
Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica. N Engl J Med. Published 3 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →